Welcome to our dedicated page for Septerna news (Ticker: SEPN), a resource for investors and traders seeking the latest updates and insights on Septerna stock.
Septerna, Inc. (Nasdaq: SEPN) is a clinical-stage biotechnology company focused on G protein-coupled receptor (GPCR) drug discovery and development. News about Septerna often centers on progress across its pipeline of oral small molecule GPCR-targeted therapies, updates on clinical and preclinical programs, and developments related to its proprietary Native Complex Platform™.
Investors following SEPN news can expect regular updates on key programs such as SEP-631, a selective oral small molecule MRGPRX2 negative allosteric modulator (NAM) in a Phase 1 clinical trial for chronic spontaneous urticaria and other mast cell-driven diseases, and SEP-479, a next-generation oral PTH1R agonist development candidate for hypoparathyroidism. Septerna’s news flow also includes information on its TSHR NAM program for Graves’ disease and thyroid eye disease and discovery-stage programs in endocrinology, immunology and inflammation, metabolic diseases and additional therapeutic areas.
Company announcements frequently highlight financial results, cash position and collaboration-related revenue, particularly from its global collaboration and license agreement with Novo Nordisk A/S to discover and develop oral small molecule therapies for obesity, type 2 diabetes and other cardiometabolic diseases. Septerna also issues news on corporate governance and leadership, such as board appointments, executive role changes and the formation of board committees.
In addition, Septerna regularly announces participation in major healthcare and investor conferences, where management presents business updates and pipeline overviews. For those tracking SEPN, this news page aggregates press releases and related coverage so readers can monitor clinical milestones, collaboration developments, financial disclosures and leadership changes over time.
Septerna (SEPN) granted a non-qualified stock option for up to 275,000 common shares to newly appointed Chief Medical Officer Rajiv Patni, M.D., under its 2026 Inducement Plan, effective September 8, 2026.
The option was issued as an inducement to employment in reliance on Nasdaq Listing Rule 5635(c)(4). It has a ten-year term and an exercise price of $37.37 per share, equal to the closing price of Septerna’s common stock on the grant date. Vesting occurs over four years: 25% of the shares vest on the one-year anniversary of the vesting commencement date, and the remaining 75% vest in equal monthly installments over the following 36 months, subject to Dr. Patni’s continuous employment. The grant is governed by the 2026 Inducement Plan, approved by Septerna’s board in February 2026, and by award agreements covering the option.
Septerna (Nasdaq: SEPN) announced that management will participate in two investor events in September 2026: the Wells Fargo 21st Annual Healthcare Conference with a fireside chat on September 8, 2026, at 8:00 a.m. ET, and the Cantor Global Healthcare Conference 2026 with a fireside chat on September 10, 2026, at 11:30 a.m. ET. Live webcasts and 30-day archives will be accessible via the investors section of the company’s website.
Septerna (Nasdaq: SEPN), a clinical-stage biotech focused on GPCR-targeted oral medicines, appointed Rajiv Patni, M.D., as Chief Medical Officer effective August 25, 2026. He is a physician-scientist and senior biopharmaceutical executive with over 25 years of experience in research, development, regulatory, and medical affairs.
According to Septerna, Dr. Patni has led or contributed to programs resulting in 10 regulatory approvals or label expansions across the United States, Europe and other markets. His prior roles include CEO of Judo Bio, Chief Research and Development Officer at Reata Pharmaceuticals, and CMO positions at several publicly traded biopharma companies.
Septerna (Nasdaq: SEPN) reported second quarter 2026 results and highlighted progress across its GPCR-focused pipeline. The Phase 1 trial of SEP-479, an oral PTH1R agonist for hypoparathyroidism, is ongoing; pharmacokinetic data show an elimination half-life of approximately three to four days, supporting once-daily dosing. Single- and multiple-ascending dose data are now expected in Q1 2027 after extending MAD dosing to 14 days.
SEP-631, an oral MRGPRX2 NAM, previously showed positive Phase 1 safety and pharmacodynamic results, and the company is exploring capital-efficient studies in mast cell-driven diseases. Revenue rose to $26.7 million, mainly from the Novo Nordisk collaboration, while net loss narrowed to $13.0 million. Cash, cash equivalents and marketable securities were $516.5 million, which Septerna expects will fund operations at least into 2029.
Septerna (Nasdaq: SEPN) will present preclinical data on SEP-479, an oral small molecule PTH1R agonist for hypoparathyroidism, at ENDO 2026 on June 13 in Chicago.
The drug is in an ongoing Phase 1 SAD/MAD study in healthy volunteers, with data expected in late 2026 or early 2027.
Septerna (Nasdaq: SEPN) reported Q1 2026 results and pipeline progress. Cash, cash equivalents and marketable securities totaled $522.1 million, with a runway expected at least into 2029.
Highlights include positive Phase 1 data for SEP-631, initiation of a Phase 1 trial for SEP-479, and $26.5 million in collaboration revenue.
Septerna (Nasdaq: SEPN) said CEO and co-founder Jeffrey Finer, M.D., Ph.D. will present at the Bank of America Securities Health Care Conference on May 12, 2026 at 5:00 p.m. PT in Las Vegas.
A live webcast will be available on the company investor site and archived for at least 30 days.
Septerna (Nasdaq: SEPN) has dosed the first participants in a Phase 1 trial of SEP-479, an oral small-molecule PTH1R agonist for hypoparathyroidism. The randomized, placebo-controlled SAD/MAD study will enroll up to 150 healthy adults and assess safety, tolerability, PK and PD.
Key secondary/exploratory PD endpoints include changes in endogenous PTH, serum calcium and other biomarkers. Septerna expects to report data in late 2026 or early 2027.
Septerna (Nasdaq: SEPN) reported Q4 and full-year 2025 results and highlighted pipeline progress, including positive Phase 1 data for SEP-631 and IND-enabling completion for SEP-479. Cash totaled $548.7M at year-end, and management expects runway to support operations at least into 2029.
SEP-631 showed favorable safety, once-daily PK, and dose-dependent PD with near-complete inhibition at higher doses; Phase 2b in CSU planned in H2 2026.
Septerna (Nasdaq: SEPN) reported positive Phase 1 results for SEP-631, an oral MRGPRX2 negative allosteric modulator. SEP-631 showed dose-dependent inhibition of icatibant-induced skin wheals with complete inhibition at 10 mg once-daily and near-complete inhibition at 90–200 mg.
The drug was well tolerated, had an approximate 24-hour half-life, no food effect on exposure, and a PK profile supporting once-daily oral dosing. Septerna plans a Phase 2b CSU trial in H2 2026 pending long-term toxicology completion.